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A B S T R A C T
Hb variants are structurally abnormal haemoglobins which can originate a wide range of phenotypes from
clinically silent conditions to very severe disorders. In many cases, diagnosis is very difficult due to the in-
stability of Hb mutants or the occurrence of misleading symptoms, such as cyanosis or hypoxia. Here we report
the case of a young female with undiagnosed chronic haemolytic anaemia and low oxygen saturation in the
absence of respiratory distress. High performance liquid chromatography showed the occurrence of an abnormal
peak in the HbA2 region, which disappeared few days after blood sampling. Genetic analysis of both α genes
revealed the −α3.7 deletion in heterozygous state and a novel mutation c.130 T>C leading to the substitution
of Phenylalanine at codon 43 with Leucine in the α1 gene. This substitution originated a new Hb variant, named
Hb Vanvitelli, with a molecular mass of 15,092.2±0.4 Da. Biochemical and laboratory tests described a hyper
unstable Hb variant with altered oxygen affinity that was clinically significant only when co-inherited with
genetic defects affecting the α2 locus. This case highlights the genetic complexity and diagnostic pitfalls of Hb
variants, defined “experiments of nature” which can generate severe clinical conditions.
Background
Defects in synthesis and function of hemoglobin (Hb) are extremely
widespread, affecting about 6% of global population and millions of
people worldwide. Because of its functional role and genetic com-
plexity, Hb disorders severely impact on human health with significant
morbidity and mortality in affected patients [1]. Hb variants are
structurally abnormal haemoglobins determining a wide range of clin-
ical effects from silent to very severe disorders [2]. More than one
thousand of Hb variants have already been described with about half of
them being originated by defects in α genes [3]. Identification of Hb
variants is still challenging as often they are unstable and not detectable
by the most common diagnostic procedures (electrophoresis or chro-
matography). Patients may then undergo several and expensive la-
boratory and instrumental tests before a correct diagnosis can be for-
mulated [2]. Moreover, the presence of α chain variants might result in
a wide range of clinical features, from silent to severe phenotypes,
making the assessment of a correct diagnosis mandatory to allow ge-
netic counselling and yield new insight in haematology practice.
Here we report the case of a hyper unstable Hb variant with altered
oxygen affinity due to a novel mutation in the α1 globin gene, causing
chronic haemolytic anaemia when co-inherited with the −α3.7 dele-
tion. Diagnostic pitfalls and clinical significance are also discussed.
Case report.
A 14-year-old female from a little town near Naples, in Southern
Italy, was admitted to our outpatient clinic for evaluation of her pro-
longed and undiagnosed anaemia. The girl was the second child of non-
consanguineous parents. No issues were reported during pregnancy and
delivery. There was no family history of hereditary haemolytic anaemia
or any genetic disease. Personal history revealed recurrent abdominal
pain and exertional dyspnoea. Clinical and laboratory evaluation fol-
lowing syncope at the age of 13 years revealed haemolytic anaemia (Hb
102 g/L, MCV 87.9 fL, Reticulocytes 9.45%=351,000×106/μL, Total
Bilirubin 44.29 μmol/L, Indirect Bilirubin 38.13 μmol/L, Haptoglobin
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0 g/L, LDH 659 U/L, Serum ferritin 352.78 pmol/L, Transferrin sa-
turation 48%). Hepatosplenomegaly (longitudinal diameter of liver
130mm, spleen 145mm) was detected at abdomen ultrasound. Blood
smear showed intense anisopoikilocytosis with normal white cells and
platelets. Common tests for diagnosis of haemolytic anaemia, including
direct and indirect antiglobulin test, cold agglutinins, osmotic fragility,
high performance liquid chromatography (HPLC), antinuclear antibody
(ANA), complement component 3 (C3) resulted normal. Infection due
to hepatitis B and C virus and human immunodeficiency virus, red cell
enzyme deficiency and paroxysmal cold haemoglobinuria were ruled
out.
Laboratory Analyses: HPLC, Genetic Analysis, Hb variant detec-
tion.
Laboratory tests performed in our lab confirmed the haemolytic
anaemia with hepatosplenomegaly, and low oxygen saturation (SpO2)
at the pulse oximetry (86–88%). Oxygen saturation at co-oximetry on
arterial blood (SaO2) was 78.9% (normal: > 95%) and partial pressure
of oxygen (PaO2) was 42.6mmHg (normal range: 80–100mmHg) in
the absence of respiratory distress. A new HPLC investigation was then
performed, suspecting the occurrence of a Hb variant. The HPLC
chromatogram showed HbF and HbA2 values of 1.9% and 3.7% re-
spectively and the presence of an abnormal peak coeluting in the HbA2
region (Fig. 1). Venous P50 (oxygen tension when hemoglobin is 50%
saturated with oxygen measured by venous gas parameters according to
a mathematical formula [4,5]) was 30.37mmHg (normal value
22–26mmHg).
When the HPLC examination was again performed a few days after
blood sampling, the abnormal peak in the HbA2 area disappeared,
confirming the occurrence of an unstable Hb variant. Following in-
formed consent, a detailed investigation of the alpha and beta globin
genes was carried out.
Genomic DNA was extracted from peripheral blood leukocytes using
the Flexigene DNA Kit (Qiagen GmbH, Hilden, Germany). Complete
coding and intronic sequences of HBA1 and HBA2 genes were amplified
by polymerase chain reaction (PCR) as two long amplicons and nested
primers were used to sequence both genes. Detailed methods and
primer sequences are available on request. The PCR products were se-
quenced using the ABI 310 DNA Sequencer and the ABI PRISM Dye
Terminator Cycle Sequencing Reaction Kit (Applied Biosystems, Milan,
Italy), according to the manufacturer's instructions.
No defects were observed in the analysis of the beta gene, whereas
genetic analysis of the α genes revealed the occurrence of a−α3.7
deletion in heterozygous state and a novel mutation at codon 130 in the
α1 gene (c.130 T>C) originating the substitution of Phe43 with
Leucine (Fig. 2). Genetic investigation of the other members of the fa-
mily showed that the proband's mother was carrier of the −α3.7 dele-
tion in heterozygous state, while the father was heterozygous carrier of
the new mutation c.130 T>C in the α1 gene. Both brothers did not
display any mutation in the α and β globin genes. Family pedigree and
laboratory parameters are reported in Fig. 3.
The new Hb variant was characterised by a combination of HPLC
chromatography and mass spectrometry. A red cell lysate from the
patient was diluted 1:10 with 0.2% TFA and fractionated by reversed
phase HPLC producing the chromatogram shown in Fig. 4. Individual
globin peaks were collected and their accurate molecular weight was
determined by ES-MS on a Q-TOF hybrid instrument (Waters, Milford,
MA, USA) showing the occurrence of a normal β-globin (molecular
mass of 15,867.5±0.7 Da) and the presence of two components in the
α globin peak, a normal α-globin (molecular mass of
15,125.9± 0.9 Da) and an anomalous alpha chain displaying a mole-
cular mass of 15,092.2±0.4 Da, about 34 Da lower than the normal α
globin, indicating the occurrence of an α chain variant. The alpha
globin peak was digested with trypsin and an aliquot of the resulting
peptide mixture was directly analyzed by MALDI-MS (ABI Sciex, Fra-
mingham, MA, USA) (Fig. 5). All the mass signals in the spectrum were
mapped onto the anticipated sequence of the normal α chain on the
basis of their mass values. An anomalous mass signal occurred at m/z
1799.9 and was tentatively assigned to the abnormal peptide 41–56
with a molecular mass decreased by 34 Da. The abnormal mass signal
was then isolated in the mass spectrometer and submitted to tandem
MALDI-MS-MS analysis producing the fragmentation spectrum shown
in Fig. 6. The amino acid sequence of the abnormal peptide was de-
termined by manual inspection of the spectrum as Thr-Tyr-Leu-Pro-His-
Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Lys, corresponding to the
variated 41–56 peptide containing a Leucine residue at position 43
replacing the normally occurring Phenylalanine. The new abnormal Hb
was then defined as c.130 T>C (p.Phe43Leu) variant and named Hb
Vanvitelli. This variant shows the same amino acid replacement of Hb
Hirosaki but detected in the α1 gene.
Discussion
In case of chronic haemolytic anaemia, the occurrence of Hb var-
iants should be suspected when the most common reasons for haemo-
lysis have been ruled out [2]. Here we report the observation of a novel
mutation in the α1 globin gene, leading to the Phe43 -> Leu sub-
stitution, co-inherited with the most common deletion −α3.7. The
combined defects determined chronic haemolytic anaemia and low
SpO2 at the pulse oximetry while the novel mutation was essentially
asymptomatic in the heterozygous state showing only mild re-
ticulocytosis and normal Hb value.
On the basis of biochemical and laboratory findings, this new Hb
variant was described as a hyper unstable mutant. Hb stability is im-
paired by different recognized mechanisms, such as globin chain
elongations, amino acid deletions, alterations of secondary structure,
amino acid substitutions within the hydrophobic interior or within the
heme pocket [6]. However, mutations involving heme pocket have
been associated to multiple biochemical effects, including reduced co-
operativity, high rate of haemin loss, autooxidation and unfolding of
the globin mutants [7]. Phenylalanine at codon 43 (at the CD1 helical
region in the heme pocket) is one of the invariable residues within all
alpha chains and plays a critical role in maintaining the heme in the
proper position for interaction with the globin chains [8]. Substitution
of this Phe residue results in highly unstable Hb variants with altered
O2 affinity [2]. The same amino acid substitution was reported for Hb
Hirosaki (c.132C>G - p.Phe43Leu) [9] and Hb Sens (c.130 T>A -
p.Phe43Ile) [8] both occurring in the α2 gene. In Hb Torino
(c.130 T>G - p.Phe43Val), Phe43 was replaced by Val but it is unclear
whether the substitution occurred in the α1 or α2 gene [10]. Similar
variants due to substitution of the Phe residue at the CD1 helical region
in the heme pocket have been reported for the β chain in Hb Bruxelles
[7,11], Hb Hammersmith [12] and Hb Buccuresti-Louisville [13,14]. In
a significant proportion of these Hb variants, congenital haemolytic
anaemia and cyanosis have been reported, confirming the multiple
Fig. 1. HPLC of the patient's blood sample. The arrow indicates the abnormal
peak.
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biochemical effects due to mutations involving the heme pocket [2].
The proband showed lip cyanosis and slate gray color of the skin,
that are confusing and misleading symptoms of low O2 affinity Hb
variants [15]. The pulse oximetry revealed a low SpO2 without
respiratory distress, suggesting the possible presence of a Hb variant,
although the previously performed HPLC was normal. To date, 21 dif-
ferent Hb variants have been associated to low SpO2 and a few of them
had concordantly reduced SaO2 and/or PaO2 [16]. Pulse oximetry is a
Fig. 2. DNA sequencing chromatogram showing the novel mutation in the α1 gene.
Fig. 3. Family Pedigree (A) and Blood Parameters (B).
Fig. 4. Total ion current (TIC) profile of the LC-MS analysis of the proband's sample. The anomalous globin chain coeluted with the normal α globin. The molecular
mass of all the globins are indicated.
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non invasive spectrophotometric analysis to measure the percentage of
oxy- and deoxyhemoglobin, based on their different light absorbance
properties. Some Hb variants have a specific and unique absorption
spectrum, closer to the light absorbance of deoxyhemoglobin, leading
to the erroneous conclusion of increased deoxyHb [17–19]. Also arterial
blood gas analysis (SaO2 and PaO2) can be affected by the presence of
low O2 affinity Hb variants, as they alter the oxyhemoglobin dissocia-
tion curve and so invalidate the empirical calculation algorithm [16]. A
correct diagnosis of Hb variants associated to low pulse oximetry
measurement is convenient to avoid extensive cardio-pulmonary eva-
luation and hospital admissions to assess supposed hypoxemia and to
allow a suitable monitoring of oxygenation during anesthesia and sur-
gery [18,20]. However, in many cases, patients only received diagnosis
after several and expensive diagnostic tests to rule out the causes of
hypoxia [16].
Pitfalls in the diagnosis of hyper unstable Hb mutants have been
reported, as they tend to precipitate shortly after synthesis and are not
incorporated into Hb tetramers [2]. These ephemeral proteins are dif-
ficult to isolate making DNA sequencing a critical diagnostic test. Hb
Hirosaki (c.132C>G - p.Phe43Leu) was discovered in a family with
haemolytic anaemia [21,22] and DNA sequencing was used to char-
acterize the mutation as several tests failed to identify a soluble variant
Hb within erythrocytes.
The occurrence of an unstable variant in our proband was suspect
by the abnormal shape of the HbA2 peak in the HPLC analysis of a fresh
blood sample; this peak disappeared when the analysis was performed
few days after the sampling. We then recommend that HPLC analysis
and tests for the assessment Hb variants should be performed soon after
blood sampling, in order to increase the possibility to detect unstable
Hb variants. When separation of the globins was carried out, the alpha
variant coeluted with the normal globin and could only be detected
because of the high sensitivity of mass spectrometry. Assessment of the
amino acid substitution was then performed by tandem mass spectro-
metry on the abnormal 41–56 peptide.
Hb Vanvitelli does not have dominant effect, as reported for Hb
Torino, Hb Hirosaki and Hb Sens, but displays a pathological phenotype
only when associated with other mutations in either of the two α genes.
This observation might be related to the different transcription level of
the α1 and α2 globin genes. In physiological conditions, the α2 mRNA
level is higher than α1 mRNA by approximately 3:1 during develop-
ment, probably as a result of differences in gene transcription regula-
tion. The α2 gene encodes two- to threefold more protein than α1
suggesting a more severe phenotype associated with α globin mutations
affecting the α2 rather than the α1 locus [23]. Hb Vanvitelli, affecting
the α1 globin gene, causes silent phenotype in the heterozygous state
but relevant haemolytic anaemia when co-inherited with genetic de-
fects occurring at the α2 locus.
Highly variable clinical symptoms were reported among the mem-
bers of the same family carrying Hb Hirosaki, ranging from silent car-
riers to severely anemic patients, without clear explanation of this
discrepancy [22]. A detailed investigation of further defects occurring
in α genes in these patients might reveal detrimental effects due to
possible additional mutations, as occurred in Hb Vanvitelli.
Little is known about possible therapeutic approaches to unstable
Hb variants. Our patient is pale, jaundiced and complains recurrent
abdominal pain due to bile sludge. She missed one year of school be-
cause of profound asthenia and exertional dyspnoea. Although the ef-
fect of splenectomy is known in different form of anemias [24–29], this
Fig. 5. MALDI-MS spectrum of the tryptic digest from the variant globin chain. The mass signal corresponding to the anomalous peptide is indicated in the insert.
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procedure is reported just in very few patients affected by Hb variants
with incomplete resolution of haemolysis and/or anaemia [22]. Hy-
droxyurea is a well-established therapeutic approach in different he-
moglobinopathies, such as sickle cell disease and thalassemia syn-
dromes [30–33], but the effect on unstable Hb variant is still unclear.
Nowadays, Hb variants have widely been described in their structural
features and biochemical functions, but a general and comprehensive
therapeutic approach is far from being developed. Formation of an in-
tegrated network involving researchers and clinicians in charge of the
day-to-day care of patients might then be essential for sharing knowl-
edge on clinical evolution and long term management of these condi-
tions, as observed in other haematological conditions [34].
In conclusion, we reported a new mutation in the α1 globin gene
determining chronic haemolytic anaemia when inherited with the most
common deletion −α3.7. A familiar non spherocytic anaemia should be
assessed for unstable Hb variants when the most common forms of
haemolysis have been ruled out. The heterogeneity of clinical symp-
toms among members of the same family should suggest the possible
occurrence of an uncommon Hb variant co-inherited with other Hb
defects. In case of unstable Hb variants, diagnostic tests should be
performed soon after blood sampling to prevent variant degradation.
More studies are needed to establish the impact of therapeutic proce-
dures, such as splenectomy or hydroxyurea, on the treatment of un-
stable variant disorders.
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